The first of the therapeutic skeletal anabolic agents, parathyroid hormone (PTH), has now been on the market for more than a year. The success of this drug, coupled with recent advances in the understanding of bone formation and identification of new potential signaling molecules and targets for anabolic skeletal agents, has revolutionized the field of osteoporosis therapy. This means that clinicians and researchers can now approach osteoporosis therapeutically in two completely different ways: by slowing bone loss (the old way) and by stimulating new bone formation (the new, anabolic way).
Speakers at the May 24-25 meeting include world-renowned scientists Thomas Clemens, Ph.D., Susan Greenspan, M.D., Thomas Einhorn, M.D., Mark Johnson, Ph.D., Sundeep Khosla, M.D., and Stavros Manolagas, M.D., Ph.D.
This scientific meeting is also co-sponsored by The American Academy of Orthopaedic Surgeons, The Endocrine Society, The International Society for Clinical Densitometry, The National Institute of Diabetes and Digestive and Kidney Diseases, The National Institute on Aging, The National Institute of Arthritis and Musculoskeletal and Skin Diseases, The National Institute of Child Health and Human Development, The National Institute of Dental and Craniofacial Research, The National Osteoporosis Foundation and The Osteogenesis Imperfecta Foundation.